Seraxis, which is currently located at the Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC) in the County-owned Germantown Innovation Center is developing its lead therapy, SR-01, to eliminate the need for type 1 diabetes patients to inject insulin. SR-01 is a revolutionary therapy that could impact more than 4.5 million people in the world.
The Seraxis solution is a simple approach to diabetes. Chief Executive Officer Dr. William Rust explained that the therapy replaces damaged or lost insulin-producing pancreatic cells with those grown in the Seraxis labs. In order to accomplish this, Seraxis has developed a proprietary human stem cell line dubbed SR1423 which is special.